Fostering R&D of novel antibiotics and other technologies to prevent and treat infection

Abstract Generating innovative antibiotics is an essential part of addressing antimicrobial resistance. New policies and incentives are necessary to overcoming the multiplicity of scientific, regulatory, and economic hurdles that obstruct antibiotic discovery and development. This presentation asses...

Full description

Saved in:
Bibliographic Details
Published in:European journal of public health 2020-09, Vol.30 (Supplement_5)
Main Authors: Renwick, M, Mossialos, E
Format: Article
Language:English
Subjects:
Antibiotics
Antimicrobial agents
Antimicrobial resistance
Barriers
Dormancy
Drug resistance
Economic development
Economics
Incentives
Program implementation
Public health
R&D
Research & development
Resistance
Value
Value chain
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Generating innovative antibiotics is an essential part of addressing antimicrobial resistance. New policies and incentives are necessary to overcoming the multiplicity of scientific, regulatory, and economic hurdles that obstruct antibiotic discovery and development. This presentation assesses the changing landscape of the antibiotics market, barriers to drug discovery and development, incentive mechanisms and strategies to overcome these barriers, and the current product pipeline for antibiotics and alternative therapies. Over recent years, many incentive programmes have been implemented to foster the antibiotic value chain. This chapter proceeds to review the key multilateral, European Union, United States, United Kingdom and regulatory initiatives incentivizing antibiotic research and development. While these initiatives have helped lift the antibiotic pipeline out of dormancy, the recent progresses in development are not sufficient to counter the unrelenting advancement of antimicrobial resistance. We argue that the current global incentive package could be strengthened by ensuring that a continuum of incentives is offered to developers, reflecting the economic need, cost distribution, and barriers of the antibiotic value chain. A global governing body that provides overarching guidance to international and national-level incentive programmes will be critical to achieving such a continuum.
ISSN:1101-1262
1464-360X
DOI:10.1093/eurpub/ckaa165.1203